MP78-02 CAN WE USE SERUM 17-HYDROXYPROGESTERONE AS A SERUM BIOMARKER OF INTRATESTICULAR TESTOSTERONE?

Field: Medicine (Health Sciences)

You have accessJournal of UrologySexual Function/Dysfunction: Evaluation II (MP78)1 Apr 2020MP78-02 CAN WE USE SERUM 17-HYDROXYPROGESTERONE AS A SERUM BIOMARKER OF INTRATESTICULAR TESTOSTERONE? Thiago Lima*, Premal Patel, Ruben Blachman-Braun, Vinayak Madhusoodanan, and Ranjith Ramasamy Thiago Lima*Thiago Lima* More articles by this author , Premal PatelPremal Patel More articles by this author , Ruben Blachman-BraunRuben Blachman-Braun More articles by this author , Vinayak MadhusoodananVinayak Madhusoodanan More articles by this author , and Ranjith RamasamyRanjith Ramasamy More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000964.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Intratesticular testosterone (ITT) is essential for spermatogenesis and can only be reliably measured with invasive testicular sampling. Previous studies showed good correlation between ITT and serum 17-hydroxyprogesterone (17-OHP) in men treated with human Chorionic Gonadotropin (hCG). Based on this observation, we hypothesized that we can use serum 17-OHP as a serum biomarker for ITT in men receiving testosterone therapies. METHODS: We performed a prospective study from July 2018 to October 2019. We evaluated men undergoing agents that alter serum testosterone at baseline and after 3 months of therapy. The control group comprised of fertile men who had never received testosterone therapy. According to the data distribution, we reported the median and interquartile ranges [25-75] and utilized the Mann Whitney U or Wilcoxon tests. RESULTS: On an initial cross-sectional analysis, we evaluated 42 fertile controls, 37 men receiving Clomiphene Citrate (CC) and/or human Chorionic Gonadotropin (hCG) and 21 that received exogenous testosterone therapy (TRT). We demonstrated that serum testosterone levels were similar between men receiving the various therapies, however we found that serum 17-OHP was undetectable in men that received TRT compared to men receiving CC/hCG or fertile controls (Figure 1). Furthermore, on a prospective evaluation in men who received testosterone altering therapies, we demonstrated that serum 17-OHP decreased in men who received TRT (p < 0.05) at 3 months as compared to men who received CC/hCG (Figure 2) in whom serum 17-OHP was maintained. CONCLUSIONS: Serum 17-OHP appears to be a reliable serum marker for ITT levels. Serum 17-OHP could potentially be used in the management of men with hormonal causes of infertility, titrating and altering medications based on ITT levels rather than serum testosterone levels. Source of Funding: None. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1173-e1173 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Thiago Lima* More articles by this author Premal Patel More articles by this author Ruben Blachman-Braun More articles by this author Vinayak Madhusoodanan More articles by this author Ranjith Ramasamy More articles by this author Expand All Advertisement PDF downloadLoading ...